The Open Targets Blog

OCTOBER 24, 2023

Amir Feizi is the Director of Bioinformatics at OMass Therapeutics, a spinout from Professor Dame Carol Robinson’s Laboratory at the University of Oxford. Their work was recently published in Bioinformatics. We chat with him about otargen, and the importance of sharing open-source resources within the bioinformatics community.

Bioinformatics 63

Bioinformatics Packaging Pharmaceutical Companies Pharma Companies 63

Elrig

APRIL 29, 2024

Harini Srinivasan is a Principal Scientific Associate at Serna Bio with over 10 years of research experience in academic institutions, health care organizations and pharmaceutical companies. Bioinformatics is all about bringing together different areas of knowledge. big pharma or startups/spin off? What pro/cons?

Bioinformatics 59

Bioinformatics Drugs Molecular Biology Cell Based Assays 59

Drug Target Review

MARCH 13, 2025

Techbio companies have initiated this approach. Now even non-AI native big pharma companies take a similar view on using clinical genomics with integrated multimodality. About the authors Remco Jan Geukes Foppen , PhD, is an AI and life sciences expert specialising in the pharmaceutical sector.

Drug Development 59

Drug Development Science Clinical Trials FDA 59